Prevalence of different anti-phospholipid antibodies in systemic lupus erythematosus and their relationship with the antiphospholipid syndrome

Clinical Chemistry

Volumn 47, Issue 6 I, 2001, Pages 985-987

  Galli, M ^a   Barbui, T ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTIBODY; CALCIUM; CARDIOLIPIN ANTIBODY; HIGH MOLECULAR WEIGHT KININOGEN; LIPOCORTIN 5; LOW MOLECULAR WEIGHT KININOGEN; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PHOSPHOLIPID ANTIBODY; PLASMA PROTEIN; POLYSTYRENE; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR;

ANTIBODY DETECTION; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; BLOOD CLOTTING; CROSS REACTION; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HUMAN; PREVALENCE; PROTEIN S DEFICIENCY; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

EID: 0035019527     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.6.985     Document Type: Editorial

References (31)

1. Antiphospholipid syndrome: General features
2. A "primary" antiphospholipid syndrome?
3. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus
4. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an International Workshop
5. Lupus anticoagulant measurement
6. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay: Standardization and quantitation of results
7. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H)
8. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor
9. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants
10. Anticoagulant activity of anti-β2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies
11. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies
12. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?
13. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody
14. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex
15. Antibodies to factor XII associated with lupus anticoagulant
16. Thrombomodulin antibodies inhibit protein C activation and are found in patients with lupus anticoagulant and unexplained thrombosis
17. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome
18. Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome
19. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies
20. "Anticardiolipin" autoantibodies recognize β2-glycoprotein I in the absence of phospholipid
21. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified surface
22. Association between the prevalence of antibodies to β2-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications
23. Mechanisms and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid
24. Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction
25. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity. Discrimination between functional and non-functional anti-prothrombin-antibodies
26. Should we include anti-prothrombin antibodies in the screening for the antiphospholipid syndrome?
27. Which are the best biological markers of the antiphospholipid syndrome?
28. Inherited thrombophilia: Pathogenesis, clinical syndromes, and management
29. Displacement of factor Va by annexin V
30. Annexin V is critical in the maintenance of murine placental integrity
31. Pregnancy loss in the antiphospholipid antibody syndrome - A possible thrombogenic mechanism